Overview

This symposium will feature an array of translational research programs that integrate computational and experimental approaches to:

1. Discover novel, disease-relevant targets and biomarkers.
2. Develop next-generation animal models and target enabling tools.
3. Support the development of new candidate therapeutics for a diverse portfolio of targets.
4. Advance data-driven drug repositioning and combination therapy development.

The featured programs will include:

• Accelerating Medicines Partnership for Alzheimer’s Disease (AMP-AD) Target Discovery Program and Affiliated Consortia
• Alzheimer’s Gut Microbiome Project
• MODEL- AD Consortium
• TREAT- AD Consortium
• Translational Bioinformatics Program for Drug Repositioning and Combination Therapy Development
• Alzheimer’s Drug Development Program (ADDP)
• Alzheimer’s Clinical Trials Consortium (ACTC)

Agenda

View the agenda.

Target Audience

Academic, biotech and pharmaceutical industry researchers with interest in target and biomarker discovery, preclinical and clinical drug development; computational biologists; data scientists; and open science advocates.

Scheduling Note

Pre-recorded materials will become available on-demand beginning Monday, July 27. Live sessions will be held on Friday, July 31. All times are listed in Central Daylight Time (North America).

All pre-recorded content will be available for 30 days after the conference. ISTAART members receive extended access to the virtual platform for an additional 30 days following AAIC. Not an ISTAART member? Join today.